Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 3Non-muscular Invasive Bladder Cancer 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Therapeutic Uses × Genitourinary × Clear all
NCT06747455 2026-04-27

BCG for Therapeutic Use Phase â…¢ Clinical Trial

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Phase 3 Active not recruiting
439 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT06100653 2025-05-31

BCG for Therapeutic Use Phase I Clinical Trial

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Phase 1 Completed
10 enrolled
Genitourinary

Non-muscular Invasive Bladder Cancer

NCT06350838 2024-04-05

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

Chengdu CoenBiotech Co., Ltd

Phase 1 Completed
10 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT06241755 2024-02-05

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Chengdu CoenBiotech Co., Ltd

Phase 3 Recruiting
412 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡